Inverse correlation of concurrent BCL2, and C MYC expressions and CD30 ‎positivity as regard the Prognostic significance in diffuse large B-cell ‎lymphoma

Abstract

Background : C MYC, BCL2 and CD30 play an important role in initiation and propagation of diffuse large B-cell lymphoma (DLBCL). Protein expression of these marker were used in the diagnosis, predicting the prognosis and as a therapeutic target in DLBCL. Purpose : This study aimed to assess the prognostic impact and therapeutic utility of expression patterns of CD30, BCL2, MYC in DLBCL. Patients and Methods: This retrospective study was carried out on DLBCL diagnosed at Oncology Centre Mansoura University (2016-2019). The study was approved by IRB of Mansoura faculty of Medicine Code Number: R.23.01.2043, 21/03/2023. Results : BCL2, C MYC, concurrent BCL2, C MYC and CD30 overexpression was present in 76%, 36%,and 26% of the studied cases respectively. Concurrent expressions of BCL2, C MYC showed significant association with the presence relapse (P= 0.003). Concurrent expression of BCL2, C MYC revealed significant association with the progressive therapy response (P=0.003). In addition, C MYC, expression was significantly associated with the presence of extra-nodal presentation (P=0.03). CD30 protein overexpression was significantly associated with stage II and III (P=0.03). CD30 positivity showed inverse correlation with the concurrent expression of BCL2, C MYC (Correlation Coefficient=--.355, P=0,02). Also, CD30 positivity and concurrent expression of BCL2, C MYC reflected significant prognostic impact on overall survival (OS) and disease free survival (DFS) (all P=0.00). Conclusion: concurrent C MYC, BCL2 overexpression is associated with a lower OS, and DFS. CD30 positivity is associated with a better OS, and DFS which can be utilized in management plan of DLBCL.